Journal article
Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials.
- Birkhaeuser M a Division of Gynaecological Endocrinology and Reproductive Medicine, Department of Obstetrics & Gynaecology , University of Bern , Bern , Switzerland.
- Bitzer J b Department of Obstetrics and Gynecology , University Hospital , Basel , Switzerland.
- Braat S c MSD , Oss , The Netherlands.
- Ramos Y e MSD , Munich , Germany.
- 2019-02-05
Published in:
- Climacteric : the journal of the International Menopause Society. - 2019
Esmirtazapine
hot flush
menopause
vasomotor symptoms
Adult
Aged
Antidepressive Agents
Dose-Response Relationship, Drug
Double-Blind Method
Female
Hot Flashes
Humans
Middle Aged
Mirtazapine
Placebos
Postmenopause
Surveys and Questionnaires
Treatment Outcome
English
OBJECTIVES
Two identical 12-week, randomized, double-blind, placebo-controlled, multi-arm, parallel-group Phase III studies (Study P012, NCT00560833; Study P013, NCT00535288) evaluated the efficacy and safety of esmirtazapine, an investigational medicine, for the treatment of moderate to severe vasomotor symptoms (VMS) in postmenopausal women.
METHODS
Participants were randomized to placebo or esmirtazapine (2.25, 4.5, 9.0, or 18.0 mg). Co-primary efficacy endpoints (daily frequency and severity of moderate to severe VMS, both at weeks 4 and 12) were based on participative LogPad daily diaries. Adverse events (AEs) were recorded.
RESULTS
In Studies P012 and P013, 942 and 946 participants were randomized, respectively. Compared with placebo, esmirtazapine significantly reduced the mean daily frequency by 1.4-2.2 moderate to severe VMS at weeks 4 and 12 (both ≥4.5 mg) and mean daily severity by 0.06-0.08 symptoms at weeks 4 (≥4.5 mg) and 12 (9.0 mg P012; 18.0 mg P013 only). Esmirtazapine was generally well tolerated with a more favorable safety profile at lower doses. Somnolence and fatigue were the most frequently reported AEs.
CONCLUSIONS
Esmirtazapine reduced the frequency and severity of moderate to severe VMS associated with menopause and was generally well tolerated in the study population.
Two identical 12-week, randomized, double-blind, placebo-controlled, multi-arm, parallel-group Phase III studies (Study P012, NCT00560833; Study P013, NCT00535288) evaluated the efficacy and safety of esmirtazapine, an investigational medicine, for the treatment of moderate to severe vasomotor symptoms (VMS) in postmenopausal women.
METHODS
Participants were randomized to placebo or esmirtazapine (2.25, 4.5, 9.0, or 18.0 mg). Co-primary efficacy endpoints (daily frequency and severity of moderate to severe VMS, both at weeks 4 and 12) were based on participative LogPad daily diaries. Adverse events (AEs) were recorded.
RESULTS
In Studies P012 and P013, 942 and 946 participants were randomized, respectively. Compared with placebo, esmirtazapine significantly reduced the mean daily frequency by 1.4-2.2 moderate to severe VMS at weeks 4 and 12 (both ≥4.5 mg) and mean daily severity by 0.06-0.08 symptoms at weeks 4 (≥4.5 mg) and 12 (9.0 mg P012; 18.0 mg P013 only). Esmirtazapine was generally well tolerated with a more favorable safety profile at lower doses. Somnolence and fatigue were the most frequently reported AEs.
CONCLUSIONS
Esmirtazapine reduced the frequency and severity of moderate to severe VMS associated with menopause and was generally well tolerated in the study population.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1080/13697137.2018.1561664
- PMID 30712391
- Persistent URL
- https://sonar.ch/global/documents/285747
Statistics
Document views: 20
File downloads: